NUR-SULTAN, Kazakhstan – The National Center for Biotechnology of Kazakhstan (EFE) has presented to the country’s president, Kassym-Jomart Tokayev, a test system that allows to quickly detect a new type of coronavirus. The new tests have confirmed high sensitivity compared to foreign diagnostic drugs, Akolda reported on March 25.
“Center scientists have taken into account the ability of COVID-19 to adapt to different climatic conditions. They together with the Research Institute for Biological Safety Problems have begun work on a vaccine against coronavirus,” Akorda reported.
The President noted that the country’s authorities adopted a large-scale action plan, which includes a package of financial assistance to the population and to business. “The total cost of this package, excluding tax preferences and measures to reduce the credit burden, is more than $10 billion,” Tokayev said.
Earlier, Kazakh scientists developed vaccines against bird and swine flu, nodular dermatitis and the vector brucellosis vaccine in a short time. A total of 28 types of vaccines have been mastered. So far, 80 cases of coronavirus were confirmed in Kazakhstan.